However, mounting experience from clinical trials to date reveals the sobering fact that VEGF-targeted therapy often prolongs overall survival of cancer patients by only months and does not offer an enduring cure [18–20] or even failed entirely to reveal any evidence regarding improved quality of life [20–22]. The gene discussed is VEGFA; the disease is cancer.